Sylara AI · Cymacomm Technologies · Pleroma · Sylara Labs
A self-sustaining ecosystem that transforms fleeting inspiration into measurable, lasting vitality — powered by immersive real-world experiences and invisible agentic intelligence.
The Challenge
Gen X and Gen Z are not disengaged from wellness — they are disenchanted with products that feel inauthentic, deliver no lasting results, and handle their most sensitive health data without adequate protection or transparency.
Lack Clinical Guidance
Seven in ten consumer wellness apps operate without clinical oversight, creating direct misdiagnosis risk and ineffective care pathways at scale.
Fail to Deliver Validated Results
Most AI wellness products cannot substantiate their efficacy claims — driving a 43% Year 1 device recall rate and accelerating consumer distrust across the category.
Face Regulatory Risk
Two-thirds of digital health applications are non-compliant with HIPAA, the EU AI Act, or emerging FDA digital therapeutics frameworks — exposing investors and users alike.
People Without Basic Access
One billion people globally lack access to basic healthcare — late-stage diagnoses that proactive, scalable technology could prevent cost lives and trillions annually. (WHO, 2024)
Market Opportunity
Total Addressable Market
Global AI digital health market, 2025
(Deloitte VC Capital Trends)
Disenchanted Users
Gen X & Z actively rejecting
apps like Calm and Headspace
Serviceable SOM by 2030
Pulse OS achievable market share
targeting US and European markets
Early Momentum
Commercial validation is forming ahead of institutional capital — real demand for the technology, taking shape now.
Technology Licensing Agreement
First commercial licensing agreement for the Sylara technology stack, via Sylara Labs — currently in final contracting.
Forward-looking — agreement in final contracting; revenue not yet contracted or recognized.
Corporate Structure
Sylara AI sits at the top of the corporate stack as the parent entity — owning all data, all models, and all core IP. Every subsidiary feeds intelligence back into it, creating a flywheel that no subsidiary-level competitor can replicate.
Parent Entity · Core IP
Sylara AI
Owns all data lakes, models, and the real-time inference engine. Every interaction across all subsidiaries flows back here — compounding the intelligence asset the company holds outright.
OS · Hardware Layer
Pulse OS / Cymacomm
The software platform and all physical devices — mats, rigs, embedded sensors. Delivers Sylara's intelligence directly to users in real-world environments.
Wholly-Owned SubsidiaryExperience Layer
Pleroma
Live events, H70, podcast, content, and community. The cultural distribution engine that generates authentic real-world data and drives user acquisition.
Wholly-Owned SubsidiaryDisruptive R&D
Sylara Labs
Internal incubator for advanced research that sits outside the core product roadmap — quantum biology, novel biometric modalities, and next-generation therapeutic models.
Internal IncubatorThe Flywheel
Pleroma cultivates desire. Cymacomm powers the intelligence layer. Together they form a closed loop that continuously regenerates, strengthens, and improves itself.
01
Pleroma curates immersive events in high-energy and conscious recovery communities — creating deep emotional belonging and authentic cultural ownership.
02
Instrumented Pulse OS interfaces and embedded sensors capture rich, real-time physiological and behavioral data in natural, high-fidelity environments.
03
Sylara analyzes data in real time to deliver personalized guidance on recovery, flow-state, energy, and performance — turning inspiration into consistent, measurable results.
04
Deeper loyalty drives community growth, richer datasets, stronger Sylara models, and continuous enhancement of Pulse OS — creating compounding advantages no standalone play can replicate.
"Lifestyle is the distribution and data engine. Agentic AI is the intelligence layer."
Sylara AI
Sylara AI is the parent entity — not a product feature. It owns all data lakes, all models, and the real-time inference engine that powers the entire ecosystem. Pulse OS, Pleroma, and Sylara Labs each operate as wholly-owned subsidiaries beneath it. This structure means that every experience, every device, and every clinical interaction feeds back into a single, compounding intelligence asset that the company owns outright. The result is a defensible IP position that grows more valuable with every user interaction.
80–90% of all interactions are processed entirely on-device or within the customer's own infrastructure. Sensitive biometric and clinical data never transits a third-party cloud. Escalation to the central Sylara core occurs only when cross-module synthesis demands it — and only with cryptographic attestation of local safety compliance.
HIPAA · EU AI Act ReadySylara's ethical constraint layer is not a policy document or a content filter — it is a mathematically enforced architecture, verified at runtime via zero-knowledge machine learning proofs (zkML). Every high-stakes output generates a cryptographic attestation that Sylara's reasoning satisfied its ethical invariants before delivery. No prompt-engineering guardrail operates at this standard of provability.
zkML · ZKP ProvabilitySylara synthesizes continuous HRV time-series, vocal biomarker analysis, clinical observation data, and longitudinal behavioral patterns into a single unified inference context. This cross-domain integration produces precision that no single-modality system can approach — and compounds in accuracy over time as the individual model deepens.
NeuralKey™ IntegrationEvery Sylara output passes through an independent verifier ensemble — multiple specialized language models and a deterministic rule engine, each operating in isolation. Unanimous approval is required before any response is delivered. This layered redundancy ensures no single point of failure can produce a harmful output — a clinical-grade standard that no consumer AI product can match.
Verifier Ensemble · TEE InferenceScientific Foundation
The photobiomodulation technology powering Pulse OS immersive sessions is not speculative — it is grounded in a growing body of peer-reviewed evidence that positions water as biology's primary quantum-classical transducer.
"Water must now be regarded as an active quantum interface rather than a passive solvent. The open question is no longer whether quantum effects occur in biological water — they unequivocally do."
Paul Edge, Cymacomm Technologies — Water as a Quantum Interface, 2025Flexoelectricity in Ordinary Ice
A 2025 ICN2 consortium study demonstrated that ordinary ice generates sustained electric fields under deformation via quantum proton tunneling — providing empirical support for water as an electromechanical quantum transducer at physiological interfaces.
Nature Physics, 2025
Photobiomodulation and Water-Mediated Energy Transfer
NIR irradiation expands exclusion zones at hydrophilic surfaces. Clinical trials combining PBM with optimised hydration protocols show enhanced outcomes in PCOS, depression, and genitourinary conditions — consistent with water as an energy-distributing medium.
Lasers in Medical Science, 2024 — Journal of Women's Health, 2025
Correlated Vibrational Dynamics in Living Systems
Ultrafast 2D-IR spectroscopy at SLAC captured "quantum tugs" — excitation of one O–H stretch induces coherent oscillations in neighbouring molecules propagating with partial phase coherence for ~100 fs, approaching timescales relevant to enzymatic proton transfer.
SLAC/XLIF, Carpenter et al., 2025
Measured Impact
Early beta cohorts from Pleroma immersive events already demonstrate what peer-reviewed science predicts.
HRV Improvement
Measured in a single session — real-world immersive environment
Industry Benchmark
50% stress index reduction vs <10% category average (n=50 pilot)
Revenue Generated
Proprietary protocol licensing, events, and direct experiences (2023–2025)
What the Pilot Proved
In a pre/post cohort study of 50 participants across authentic Pleroma immersive environments, Pulse OS protocols produced a 50% reduction in stress index — more than five times the industry average for comparable digital wellness interventions (<10%). HRV is the gold-standard physiological marker of autonomic nervous system regulation; these outcomes are clinically significant, not engagement metrics.
What Comes Next
We are formalizing a third-party clinical validation trial to substantiate these outcomes for the next financing round. Post-funding, every high-value Pleroma experience will be fully instrumented with Pulse OS interfaces and embedded biometric sensors — generating the world's most authentic, contextually rich wellness dataset.
Development & Commercial Traction
Years of Foundational Development
Paul Edge's foundational scientific work — hundreds of pages of proprietary algorithms, biometric models, and coherence frameworks — mirrors the rigorous 10–15 year timeline of pharmaceutical development.
Years of Clinical Refinement
50+ deep client cases with average engagement exceeding 6 months per case — demonstrating replicability and longitudinal impact at a depth rare in pre-Series A healthcare companies.
Sold-Out Live Events
Consistent revenue-generating, sold-out in-person events demonstrating strong real-world demand, community trust, and authentic data capture at the point of experience.
BrainTap Platform Minutes
Mind Magic — one of the most-utilised tracks on BrainTap — has generated millions of platform minutes listened, accessible to thousands of licensed practitioners globally.
Rationale Brewing Partnership
Secured sponsorship with one of the fastest-growing premium non-alcoholic craft beer brands in the US — co-marketing, event activation, and access into wellness-conscious consumer communities.
No Dilution to This Point
The company has reached this level of development and commercial traction entirely on founder capital — this round represents the first external financing, with no prior dilution of the cap table.
Pulse OS
Pulse OS is the frontend through which Sylara's federated intelligence is delivered across multiple high-sensitivity B2B verticals. Each module runs a locally-installable SLM API for maximum privacy and sub-second latency — with controlled escalation to the central core when deeper reasoning is required.
NeuralKey™
Cymatics-based neurodevelopmental support module. Spectral analysis and photobiomodulation for autism support and cognitive optimization.
Physician Interface
Real-time clinical decision support, AI-assisted diagnostics, and automated documentation for EHR integration. HIPAA-compliant federated deployment.
HR Analytics
Workplace wellness intelligence for organizations. Predictive workforce health insights, stress risk stratification, and intervention timing optimization.
Women's Health
Specialized hormone tracking, fertility protocols, and cycle-informed wellness optimization with photobiomodulation-backed therapeutic interventions.
Mental Wellness
AI-driven mental health interventions with HRV-based stress forecasting, 30-day trend analytics, and crisis detection with multi-stakeholder alerts.
Vocal Analysis Interface
Voice biometric analysis for real-time emotional and physiological state detection. Feeds Sylara's representational systems analysis for adaptive communication.
HIPAA Compliant
Federated Privacy Architecture
EU AI Act Ready
High-Risk AI Classification
ZKP Verifiable
Ethical Provability Layer
Sub-Second Latency
Local SLM APIs, On-Device
Business Model
A premium subscription engine built on authentic community demand — with unit economics that compound as the Pleroma flywheel scales.
Per Month
Premium subscription — the core recurring revenue stream
CAC
Customer acquisition cost, driven down by community-led virality
LTV
Lifetime value — a ~5.5x LTV:CAC ratio
Premium Conversion
Free-to-premium conversion across the user base
The model is straightforward: 68% of Gen X/Z reject inauthentic wellness apps, and Pulse OS earns their trust through ethical, purpose-driven agentic AI. Premium subscriptions at $20/month, distributed through owned events, social, and influencer channels, scale to a projected $19.2M ARR from ~80K users by 2029 — and toward 500,000 subscribers at $120M ARR by 2030.
Go-to-Market
Community-led growth where culture is the distribution engine — a phased rollout from invite-only beta to mass premium adoption.
Phase 1
Q4 2025 – Q4 2026
Ignite the Core
StartEngine plus invite-only beta builds a 5K founding community with 20–25% conversion — seeding authentic advocates who fuel organic virality.
Phase 2
2027
Scale the Waitlist
Waitlist and social momentum scale the community to 25K, converting demand captured at events and across owned channels into a growing subscriber base.
Phase 3
2028 – 2029
Mass Rollout
Beta graduates to mass adoption — 50K free and 13K premium users, expanding toward 80K premium as the model proves out at scale.
Financial Projections
A disciplined revenue ramp toward 500,000 subscribers by 2030. Figures are forward-looking projections, not booked revenue.
2030 target: 500,000 subscribers @ $20/month — $120M ARR
Competitive Advantage
We do not compete for the same disengaged users — we win the 268M who have already rejected the incumbents.
| Pulse OS | Calm | Headspace | Cognito Therapeutics | |
|---|---|---|---|---|
| Cultural Resonance | ✓ | — | — | — |
| Blockchain Security | ✓ | — | — | — |
| Native Continuous HRV / Biophotonics | ✓ | — | — | ✓ |
| Proprietary Federated Agentic AI | ✓ | — | — | — |
| Science-Backed Innovation | ✓ | — | ✓ | ✓ |
| Interoperable Red Flag System | ✓ | — | — | — |
The Team
Cymacomm's leadership carries deep operational experience from some of the world's most demanding institutions — and the scientific bench strength to match. This is not a team building its first product. It is a team that has already operated at scale in regulated, high-stakes environments.
Competence & Expertise
Proven at Scale
Cymacomm's C-suite, with proven operational expertise from NASA, CDC, DHA, UNHCR, and the VA, powers Pulse OS. 11 PhDs in neuroscience, HRV, and health research ensure that long-term scalability is founded on scientific principles and purpose-driven values.
Leadership & Vision
The Bold Mandate
Our female CEO leads the bold vision of transforming preventative healthcare through proprietary, ethical AI for gold-standard diagnostics. Backed by a board incorporating R&D and health experts, Pulse is poised to be the iPhone of the health-tech market.
Integrity & Commitment
Fiscal Discipline
Cymacomm's ironclad fiscal system, led by a financial diligence team incorporating Morgan Stanley, Deloitte, and PwC expertise in Series A funding, IPO, and wealth management, ensures rock-solid financial stability for sustainable growth.
Team Dynamics & Collaboration
Aligned by Design
Paul Edge, Cymacomm's visionary founder and global movement expert, meticulously designed the corporate system to align each team member in a clearly defined role, fostering trust, open communication, and a unified vision. Every member's commitment, shown through 2-year contracts at half market rates, ensures scalable collaboration and long-term success.
A scientific advisory and research bench of 11 doctoral researchers specialising in neuroscience, heart rate variability, quantum biology, and population health — ensuring that every platform decision is grounded in peer-reviewed evidence and long-term scientific credibility.
Defensibility
Most competitors rely on generic APIs or bolt-on models. Our advantage compounds over time across three distinct and interlocking dimensions.
Moat 01
Pleroma creates belonging and narrative control in high-engagement communities — high-energy movement and conscious recovery scenes where trust, identity, and inspiration converge. This emotional loyalty is impossible to replicate with a technology product alone.
Moat 02
Authentic usage in targeted immersive settings generates exclusive, context-rich physiological and behavioral training data. This dataset cannot be synthesized or purchased — it is captured only through real Pleroma experiences, creating a data advantage that widens continuously.
Moat 03
Sylara is built from scratch on a mathematically enforced ethical architecture — not retrofitted with guardrails after the fact. A proprietary zkML constraint layer generates cryptographic proof that every high-stakes output satisfied Sylara's ethical invariants at runtime. This is a defensible technical position that becomes a significant regulatory asset as AI oversight tightens globally.
Moat 04
83 high-conviction patent families already identified across biophotonics, epigenetics, and ethical AI architecture — with a post-funding roadmap to exceed 150. Combined with 17+ years of foundational R&D depth, this creates a protected IP position that cannot be replicated by a well-funded competitor entering today.
Comparable Models
Connect
We welcome conversations with investors and partners who see the power of culture fused with intelligence as the future of impactful innovation.
For Investors
We are raising to instrument Pleroma experiences at scale, accelerate Sylara's proprietary model development, and launch third-party clinical validation. Detailed models, live demonstrations, and supporting materials available on request.
Speak with Investor RelationsFor Experience Partners
If you are a wellness organization, performance community, or healthcare institution looking to bring the Pleroma ecosystem to your audience — we are actively building our partner network for Phase Two deployment.
Talk to our Founder